NCT00507247View on ClinicalTrials.gov

Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

September 30, 2012

Conditions
Staphylococcus Aureus
Interventions
DRUG

Daptomycin

6mg/kg/day IV for at least 10 days.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00507247 - Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus | Biotech Hunter | Biotech Hunter